凝血因子II胆固醇受体作为乳腺癌管理中的有前途的生物标志物
Yan-Ming Dong1, Guo-Qiang Bao1
1Department of General Surgery, The Second Affiliated Hospital of Air Force Medical University, No. 356 of Xinsi Road, Baqiao District, Xi'an, 710038, China.
Open life sciences
|December 10, 2024
概括
凝血因子II血栓受体 (F2R) 在乳腺癌 (BC) 中被上调,与更好的预后和对达沙替尼的敏感性增加相关. F2R显示出作为一个有价值的BC生物标志物的潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 凝血因子II血栓受体 (F2R),也称为PAR1,在各种生理和病理过程中发挥作用.
- 它在乳腺癌 (BC) 中的特定作用和生物标志物潜力仍然不完全理解.
研究的目的:
- 研究F2R在乳腺癌中的表达和功能.
- 评估F2R作为BC的潜在诊断和预后生物标志物.
- 探索F2R与BC中的临床参数和治疗敏感性的关联.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据库进行BC数据分析.
- 进行丰富分析,瘤免疫微环境评估和药物敏感性测试.
- 进行了分子对接和基于细胞的实验,以验证发现.
主要成果:
- 在BC组织中证实F2R的显著上调,与良好的预后相关.
- 在F2R表达和雌激素/孕激素受体状态之间发现了强烈的相关性.
- 确定了与参与细胞循环,新陈代谢和免疫调节的基因 (例如CD200,NRP1) 的F2R共同表达.
- 证明F2R表达和对达沙替尼的敏感性之间存在正相关性.
结论:
- F2R是乳腺癌的一个有前途的生物标志物,表明更好的预后.
- F2R表达与BC的关键临床特征和免疫微环境组件有关.
- F2R可以预测对达沙替尼布等向疗法的反应,提供治疗见解.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Coagulation
4.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
4.7K
Extrinsic and Intrinsic Pathways of Hemostasis
5.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.5K
Clot Retraction and Fibrinolysis
4.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.0K


